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The assumption underlying current diabetes treatment
is that lowering the level of time-averaged glucose
concentrations, measured as HbA1c, prevents microvas-
cular complications. However, 89% of variation in risk of
retinopathy, microalbuminuria, or albuminuria is due to
elements of glycemia not captured by mean HbA1c val-
ues. We show that transient exposure to high glucose
activates a multicomponent feedback loop that causes
a stable left shift of the glucose concentration-reactive
oxygen species (ROS) dose-response curve. Feedback
loop disruption by the GLP-1 cleavage product GLP-1(9–
36)amide reverses the persistent left shift, thereby nor-
malizing persistent overproduction of ROS and its path-
ophysiologic consequences. These data suggest that
hyperglycemic spikes high enough to activate persistent
ROS production during subsequent periods of normal
glycemia but too brief to affect the HbA1c value are a
major determinant of the 89% of diabetes complications
risk not captured by HbA1c. The phenomenon and
mechanism described in this study provide a basis for
the development of both new biomarkers to comple-
ment HbA1c and novel therapeutic agents, including
GLP-1(9–36)amide, for the prevention and treatment of
diabetes complications.
The assumption underlying current clinical treatment of
type 1 diabetes is that lowering the level of time-averaged
glucose concentrations, measured as HbA1c, prevents the
development and progression of vascular complications.
This current treatment recommendation, adopted by di-
abetes professional societies around the world, is based on
data from the Diabetes Control and Complications Trial
(DCCT) (1), where the intensive treatment group had
a 73% reduction in risk of sustained retinopathy progres-
sion compared with the standard treatment group.
Of note, subsequent analysis of DCCT data by the
DCCT/Epidemiology of Diabetes Interventions and Com-
plications (EDIC) Research Group showed that for the
entire study population, HbA1c values explained only 6.6–
11% of the risk of retinopathy, albuminuria, or microal-
buminuria. The DCCT/EDIC Research Group concluded
that the unexplained 89% of variation in risk is due to
elements of glycemia not captured by mean HbA1c values
(2,3). The nature and identity of those elements are not
yet understood.
HbA1c represents the time-averaged mean level of gly-
cemia and thus provides no information about how
closely the fluctuations of blood glucose levels around
that mean mimic the normal narrow range of blood glu-
cose excursion. Continuous glucose monitoring data show
that in patients with type 1 diabetes with identical HbA1c
values, amplitude and duration of glycemic spikes differ
significantly (4). This suggests to us that a potential major
determinant of complications not captured by HbA1c
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could be hyperglycemic spikes high enough to activate
complication-causing mechanisms but too brief to affect
the HbA1c value (5).
Because hyperglycemia-induced overproduction of mito-
chondrial reactive oxygen species (ROS) initiates many of
the complex series of molecular events that result in
diabetic tissue damage (6), we hypothesized that transient
exposure to high glucose causes persistent mitochondrial
overproduction of ROS during subsequent prolonged peri-
ods of normal glucose. Mitochondrial ROS generation in-
creases when the inner mitochondrial transmembrane
potential (DC) exceeds a threshold level (7). Maintaining
a constant level of DC requires binding of the glycolytic
enzyme hexokinase II (HK-II) to the outer mitochondrial
membrane protein VDAC (voltage-dependent anion chan-
nel). The HK-II/VDAC association is regulated by several
mechanisms (8–10). Because activated glycogen synthase
kinase-3b (GSK-3b) phosphorylates VDAC in the mitochon-
drial outer membrane of HeLa cells, preventing VDAC as-
sociation with hexokinase (11), we speculated that in
vascular cells, activation of GSK-3b by transient hypergly-
cemia could be a critical element in a multicomponent feed-
back loop that would maintain persistently increased ROS
production during subsequent periods of normoglycemia.
GLP-1(9–36)amide, originally considered to be an inac-
tive degradation product of GLP-1(7–36)amide, has impor-
tant physiologic effects distinct from GLP-1 (12). In
hippocampal slices from the APP/presenilin 1 (PS1)
mouse model of Alzheimer disease, continuous exposure
to this GLP-1 cleavage product reduced elevated mito-
chondrial superoxide and increased levels of the inhibi-
tory phosphorylation of GSK-3b at serine 9 (13).
In the current study, we show that transient exposure
to high glucose activates a multicomponent feedback loop
involving mitochondrial superoxide-induced release of free
iron and H2O2. As a consequence, protein phosphatase 2
(PP2A) is activated and dephosphorylates Akt1, reducing
its activity. Reduced Akt1 activity decreases inhibitory
phosphorylation of GSK-3b, resulting in increased phos-
phorylation of VDAC. Impaired association of phosphory-
lated VDAC with the glycolytic enzyme hexokinase causes
a stable left shift of the glucose concentration-ROS dose-
response curve (Fig. 3). Feedback loop disruption by the
GLP-1 cleavage product GLP-1(9–36)amide reverses the per-
sistent left shift, thereby normalizing persistent ROS pro-
duction and its pathophysiologic consequences in cultured
endothelial cells and in mice after transient hyperglycemia.
RESEARCH DESIGN AND METHODS
Cell Culture Conditions and Materials
Human aortic endothelial cells (HAECs) were from
Invitrogen (Grand Island, NY) and maintained in endo-
thelial cell growth medium-2 containing 0.4% FBS plus
growth factor additives obtained from Lonza (Walkersville,
MD). Microcystin, okadaic acid, and deferoxamine mesy-
late used at 25 nmol/L, 0.1 mg/mL, and 100 mmol/L,
respectively, were from Sigma-Aldrich (St. Louis, MO).
[g32P]ATP was from GE Healthcare Life Sciences (Piscataway,
NJ). TAT-Scr and TAT-HK peptides used at 10 mmol/L
were synthesized as previously described (14). To prevent
TAT-HK–induced cell death (14), cells treated with TAT-
HK and TAT-Scr were pretreated for 1 h with 1 mmol/L
cyclosporin A. GLP-1(9–36)amide used at 100 pmol/L was
from Bachem (Torrance, CA). GSK-3b inhibitory peptide
used at 10 mmol/L was obtained from EMD (San Diego,
CA). Antibodies to GSK-3b, p-GSK-3b (S9), HK-II, and
VDAC were from Cell Signaling Technology (Danvers,
MA), BD Bioscience (San Diego, CA), and Santa Cruz Bio-
technology (Dallas, TX), respectively. Antibodies to p-Thr
were from Invitrogen. Mitochondrial isoform of superoxide
dismutase (Mn-SOD), empty vector, and catalase adenovi-
rus were obtained as previously described (15). Constitu-
tively active GSK-3b adenovirus and plasmids containing
constitutively activated Akt1 (Akt-1CA) and dominant neg-
ative Akt (Akt-DN) were gifts from M. Birnbaum, Univer-
sity of Pennsylvania. Akt-1CA and Akt-DN cDNAs were
subcloned into a shuttle vector for adenoviral particle pack-
aging (15). Adenoviruses were used at a multiplicity of in-
fection of 100. Six- to 8-week-old C57BL/6 mice were
purchased from The Jackson Laboratory (Bar Harbor, ME).
ROS Measurement
Cells were plated in 96-well cell culture plates. Intracellular
ROS were detected using the fluorescent probe CM-
H2DCFDA, which reacts with superoxide, H2O2, hydroxyl
radical, and ONOO2. Cells were loaded with 10 mmol/L
CM-H2DCFDA after two washes with no phenol red min-
imum essential medium, incubated for 45 min at 37°C, and
analyzed with an HTS 7000 Bio Assay Fluorescent Plate
Reader (PerkinElmer) using the HTSoft program (16).
Mitochondrial Membrane Potential Measurement
Mitochondrial membrane potential was assessed using
JC-1 dye from Life Technologies.
Immunoprecipitation and Western Blotting
Immunoprecipitation (IP) and Western blot (WB) experi-
ments were performed as previously described (15).
Determination of Kinase Activity
GSK-3b and Akt1 activities were measured using a kit
from Sigma-Aldrich and Cell Signaling Technology, respec-
tively. The effect of GLP-1(9–36)amide on Akt1 activity was
measured as described in the Supplementary Data.
Determination of PP2A Activity
PP2A activity was analyzed using a kit from R&D Systems.
Determination of Intracellular Free Iron
Free iron was measured by electron paramagnetic reso-
nance (EPR) using a modification of the method described
by Srinivasan et al. (17). See Supplementary Data for
details.
Induction of Transient Hyperglycemia in Nondiabetic,
Normoglycemic Mice
Transient hyperglycemia was induced as previously de-
scribed (18).
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Prostacyclin Synthase Activity
Prostacyclin synthase (PGI2) activity was measured by de-
termination of 6-keto-PGF-1a as previously described (19).
Statistics
ROS data are expressed as mean 6 SEM. All other data
are expressed as mean 6 SD. ANOVA in conjunction with
the Tukey-Kramer test was used for comparison of exper-
imental groups. Statistical analyses were performed using
PHStat2 software.
RESULTS
Transient Exposure to High Glucose Induces
Persistent Mitochondrial ROS Production by Shifting
the Glucose Concentration-ROS Curve to the Left
Exposure of HAECs to 25 mmol/L glucose for 6 h induced
a 2.5-fold increase in ROS production (Fig. 1A, bar 2). Of
note, the increase in ROS production induced by 6 h of 25
mmol/L glucose persisted for 2 days of subsequent incuba-
tion in 5 mmol/L glucose (Fig. 1A, bar 3). The increased ROS
production induced by transient high glucose was prevented
by overexpression of Mn-SOD (Fig. 1A, bar 4). Mn-SOD
overexpression was confirmed by Western blot (data available
on request). Cu/Zn-SOD also prevented a high glucose–
induced increased ROS (Supplementary Fig. 1). The
observations that both Mn-SOD and Cu/Zn-SOD prevent
glucose-induced ROS are best explained by a mitochondrial
origin of superoxide with Cu/Zn-SOD carrying out dismuta-
tion in the mitochondrial intermembrane space. To deter-
mine the exposure time necessary to reach the ROS levels
observed at 6 h, a time course experiment was performed in
which HAECs were exposed to 25 mmol/L glucose for in-
creasing times up to 6 h (Fig. 1B). Maximal ROS levels were
reached at 1 h and unchanged after 2–6 h exposure to high
glucose (Fig. 1B). Because maximal ROS levels were reached
after 1 h of exposure to 25 mmol/L glucose, a similar time-
course experiment was performed to determine how many
hours of transient high glucose were required to induce
persistent elevation of ROS production after 2 days’ expo-
sure to 5 mmol/L glucose (Fig. 1C). Although only 1 h of
exposure to 25 mmol/L glucose was sufficient to induce
maximal ROS production (Fig. 1B), induction of persistent
elevation of ROS production for 2 days of subsequent ex-
posure to 5 mmol/L glucose required a minimum of 4 h
transient exposure to 25 mmol/L glucose (Fig. 1C).
To understand how 6 h of exposure to 25 mmol/L
glucose caused persistent elevation of ROS production
during 2 days of subsequent exposure to 5 mmol/L
glucose, cells were incubated for 6 h in either 5 or 25
mmol/L glucose. Both groups of cells were then incubated
in 5 mmol/L glucose for 2 days. After that 2-day in-
cubation in 5 mmol/L glucose, cells from both groups were
exposed to various concentrations of glucose for 6 h
and ROS measured using CM-H2DCFDA (Fig. 1D).
In the dose-response curve from cells exposed only to 5
mmol/L glucose, ROS production did not increase signifi-
cantly between glucose concentrations of 5 and 8 mmol/L.
From 9 to 12 mmol/L glucose, ROS production increased
rapidly until reaching a maximum at 12 mmol/L. Further
increases in ROS were not induced by exposure to higher
concentrations of glucose. In contrast, cells transiently
preexposed to 25 mmol/L glucose showed a left shift in
the glucose concentration-ROS dose-response curves after 2
days’ exposure to 5 mmol/L glucose. In these cells, ROS
production increased rapidly from 2.5 to 5 mmol/L glucose,
reaching the same maximal level at 5 mmol/L glucose as the
maximal level reached at 12 mmol/L in cells incubated only
in 5 mmol/L glucose. Further increases in ROS were not
induced by exposure to concentrations of glucose.5 mmol/L.
Persistent Mitochondrial ROS Production After
Transient Exposure to High Glucose Is Maintained by
a Multicomponent Feedback Loop
Transient Exposure to High Glucose Induces
a Persistent Reduction in HK-II/VDAC Association
Mitochondrial ROS generation increases when DC
exceeds a threshold level (7). Maintaining a constant level
of DC requires binding of the glycolytic enzyme HK-II to
the outer mitochondrial membrane protein VDAC. This
binding regulates shuttling of ATP out of and ADP into
the mitochondrial matrix.
In HAECs, DC and ROS were both increased by 6 h of
exposure to 25 mmol/L glucose (Fig. 2A, top and bottom
panels). In 5 mmol/L glucose, dissociation of HK-II from
VDAC induced by a cell-permeable HK-II N-terminal pep-
tide, HK-TAT (14), caused an increase in HAEC DC and
ROS identical to that induced by exposure to 25 mmol/L
glucose for 6 h (Fig. 2A, top and bottom panels). More-
over, maximal respiration was reduced by ;38% after 6 h
of exposure to 25 mmol/L glucose (Supplementary Fig. 2).
This result suggests that oxidative damage to enzymes of
the tricarboxylic acid cycle, the electron transport chain
(ETC), or the inner mitochondrial membrane lipids oc-
curred by 6 h of 25 mmol/L glucose incubation (20,21).
Because dissociation of HK-II from VDAC in the
presence of 5 mmol/L glucose increased HAEC DC and
ROS production to the same extent as exposure of these
cells to 25 mmol/L glucose, we next asked whether exposure
of HAECs to 25 mmol/L glucose would cause dissociation of
HK-II from VDAC. The association of HK-II with VDAC was
evaluated by coimmunoprecipitation (IP:VDAC, WB:HK-II)
after 1, 2, 3, 4, 5, and 6 h of exposure of HAECs to 25
mmol/L glucose (Fig. 2B). HK-II/VDAC association was re-
duced by 50% at 3 h and by 75% at 6 h. Consistent with the
persistence of increased ROS production in 5 mmol/L glu-
cose after transient exposure to 25 mmol/L glucose, the
HK-II dissociation from VDAC induced by 6 h of exposure
to 25 mmol/L glucose also persisted for 2 days of subse-
quent exposure to 5 mmol/L glucose (Fig. 2B, red bar).
HK-II/VDAC association is regulated by several mecha-
nisms (8–10). VDAC threonine phosphorylation by GSK-3b
causes detachment of HK-II from VDAC (8). To determine
whether the HK-II/VDAC dissociation induced by transient
exposure to high glucose was caused by increased threonine
VDAC phosphorylation, IP-WB experiments were performed
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Figure 1—Transient exposure to high glucose induces persistent mitochondrial ROS production by shifting the glucose concentration-ROS
curve to the left. A: ROS levels in HAECs exposed to 25 mmol/L glucose for 6 h (green bar) and 25 mmol/L glucose for 6 h followed by
2 days (d) of subsequent incubation in 5 mmol/L glucose (red bars). In the indicated groups, cells were infected with Mn-SOD or control
adenoviral vectors before transient exposure to 25 mmol/L glucose. B: ROS levels in HAECs exposed to 25 mmol/L glucose for varying
times. C: ROS levels after 2 days of incubation in 5 mmol/L glucose following transient exposure to 25 mmol/L glucose for varying times.
D: Glucose concentration-ROS dose-response curves from HAECs transiently exposed to 25 mmol/L glucose (6 h) and then to 5 mmol/L
glucose for 2 days (red line) and from HAECs exposed to 5 mmol/L glucose for 6 h continued for 2 days (blue line). ROS levels were
measured by CM-H2DCFDA. Data are mean 6 SEM from three independent experiments with at least eight technical replicates. *P < 0.05.
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Figure 2—Persistent mitochondrial ROS production after transient exposure to high glucose is maintained by activation of a multicomponent
feedback loop. A: Inner mitochondrial transmembrane potential and ROS level in HAECs after transient exposure to 25 mmol/L glucose or
dissociation of HK-II from VDAC with the cell-permeable HK-II N-terminal peptide HK-TAT in 5 mmol/L glucose. Top panel shows representative
photomicrographs of increased JC-1 red fluorescence, indicating increased mitochondrial membrane potential. Bottom panel shows ROS
production measured by CM-H2DCFDA. B–G: HAECs were exposed to 25 mmol/L glucose for the indicated times with (red bars) or without
(green bars) subsequent incubation in 5 mmol/L glucose for 2 days (d). Cells exposed to 5 mmol/L glucose were used as controls (blue bars). B:
HK-II/VDAC association after transient exposure of HAECs to high glucose, after 2 days of 5 mmol/L glucose following 6 h of 25 mmol/L
glucose, and after 6 h of exposure to 25 mmol/L in the presence of a peptide inhibitor of GSK-3b. Top panel shows IP-WB of VDAC:VDAC and
VDAC:HK-II. Bottom panel shows quantitation of IP-WB data from top panel. C: VDAC phosphorylation after transient exposure of HAECs to
high glucose, after 2 days of 5 mmol/L glucose following 6 h of 25 mmol/L glucose, and after 6 h of exposure to 25 mmol/L in the presence of
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after 1, 2, 3, 4, 5, and 6 h of exposure to 25 mmol/L, HAECs
were collected, and cell lysates were immunoprecipitated
with an antibody against VDAC. Phosphorylation of VDAC
was evaluated using a p-Thr antibody. High-glucose treat-
ment induced a significant increase in VDAC phosphoryla-
tion starting at 3 h (Fig. 2C). Increased VDAC threonine
phosphorylation reached a maximum at 6 h (Fig. 2C). Con-
sistent with the persistence of a decreased HK-II/VDAC
association in 5 mmol/L glucose after transient exposure
to 25 mmol/L glucose, VDAC phosphorylation induced by
6 h of exposure to 25 mmol/L glucose also persisted for 2
days of subsequent exposure to 5 mmol/L glucose (Fig. 2C,
red bar). To demonstrate that the increased VDAC phos-
phorylation and subsequent dissociation of HK-II was me-
diated by GSK-3b, a cell-permeable peptide inhibitor of the
kinase was used. Pretreatment with this inhibitor prevented
both the high glucose–induced increase in VDAC threonine
phosphorylation and the resulting HK-II/VDAC dissociation
(Fig. 2B and C).
Transient Exposure to High Glucose Induces
a Persistent Increase in GSK-3b Activity
Because these data suggest that high glucose increases
GSK-3b activity, causing increased VDAC phosphorylation and
consequent HK-II/VDAC dissociation, GSK3b activity was
assessed directly by 32P incorporation into a specific GSK-3b
substrate in HAECs treated for 1, 2, 3, 4, 5, and 6 h with
25 mmol/L glucose (Fig. 2D). High glucose induced a signif-
icant increase in GSK-3b activity starting at 3 h, which
reached a maximum at 6 h. These data mirror the time
course of the increase in VDAC threonine phosphorylation
induced by high glucose. Consistent with the persistence of
increased VDAC threonine phosphorylation in 5 mmol/L
glucose after transient exposure to 25 mmol/L glucose,
increased GSK-3b activity induced by 6 h of exposure to
25 mmol/L glucose also persisted for 2 days of subse-
quent exposure to 5 mmol/L glucose (Fig. 2D, red bar).
Transient Exposure to High Glucose Induces
a Persistent Decrease in Akt1 Activity
GSK-3b activity is controlled by the phosphorylation of
specific residues by other kinases and is inhibited by
phosphorylation at serine 9 by Akt, ILK, PKA, p90RSK,
and PKC (9,10,22). Because increased GSK-3b activity in-
duced by high glucose was prevented by overexpression of
Akt-1CA (Fig. 2D), Akt1 activity was determined in HAECs
exposed to high glucose. Cells were exposed to 25 mmol/L
glucose, and Akt1 activity was measured 1, 2, 3, 4, 5, and
6 h after treatment. High glucose induced a significant de-
crease in Akt1 activity starting at 3 h, with activity reduced
by 60% at 6 h (Fig. 2E). Consistent with the persistence of
increased GSK-3b activity in 5 mmol/L glucose after tran-
sient exposure to 25 mmol/L glucose, decreased Akt1 ac-
tivity induced by 6 h of exposure to 25 mmol/L glucose also
persisted for 2 days of subsequent exposure to 5 mmol/L
glucose (Fig. 2E, red bar).
Akt1 is activated by phosphoinositide 3-kinase–dependent
phosphorylation at Ser473 and Thr308. Akt1 can be inac-
tivated by several protein phosphatases, including PP2A,
the lipid protein phosphatase PTEN, and PHLPP2 (23,24).
Treatment with either of two PP2A-specific inhibitors,
microcystin and okadaic acid, completely prevented the
high glucose–induced decrease in Akt1 activity, suggesting
that high glucose increases the activity of this phosphatase
(Fig. 2E).
Transient Exposure to High Glucose Induces
a Persistent Increase in PP2A Activity
Because PP2A inhibition prevented the decrease in Akt1
activity induced by high glucose, PP2A activity was then
measured in HAECs treated for 1, 2, 3, 4, 5, and 6 h with 25
mmol/L glucose (Fig. 2F). High-glucose treatment induced
a significant increase in PP2A activity by 2 h (2.7-fold) and
reached a sixfold increase of control activity at 6 h (Fig. 2F).
Consistent with the persistence of reduced Akt1 activity in
5 mmol/L glucose after transient exposure to 25 mmol/L
glucose, increased PP2A activity induced by 6 h of exposure
to 25 mmol/L glucose also persisted for 2 days of subsequent
exposure to 5 mmol/L glucose (Fig. 2F, red bar). Overexpres-
sion of Mn-SOD prevented high glucose–induced PP2A
activation (Fig. 2F), demonstrating that increased mito-
chondrial superoxide production was necessary for PP2A
activation by high glucose. Overexpression of catalase
a peptide inhibitor of GSK-3b. Top panel shows IP-WB of VDAC:VDAC and VDAC:P-Thr. Bottom panel shows quantitation of IP-WB data
from top panel. D: GSK-3b activity after transient exposure of HAECs to high glucose, after 2 days of 5 mmol/L glucose following 6 h of 25
mmol/L glucose, and after 6 h of exposure to 25 mmol/L in the presence of adenoviral (Ad) Akt-1CA. Activity was measured by 32P in-
corporation into a GSK-3b–specific substrate. E: Akt1 activity after transient exposure of HAECs to high glucose, after 2 days of 5 mmol/L
glucose following 6 h of 25 mmol/L glucose, and after 6 h of exposure to 25 mmol/L in the presence of PP2A inhibitors. F: PP2A activity
after transient exposure of HAECs to high glucose, after 2 days of 5 mmol/L glucose following 6 h of 25 mmol/L glucose, and after 6 h of
exposure to 25 mmol/L in the presence of Ad-Mn-SOD, Ad-catalase, or deferoxamine. G: Free iron concentration after transient exposure
of HAECs to high glucose, after 2 days of 5 mmol/L glucose following 6 h of 25 mmol/L glucose, and after 6 h of exposure to 25 mmol/L in
the presence of Ad-Mn-SOD. Free iron in HAECs was measured by EPR. H: Effect of Akt-DN or GSK-3b-CA on inner mitochondrial
transmembrane potential and ROS level in HAECs in 5 mmol/L glucose. HAECs were exposed to 5 mmol/L glucose for 6 h after infection
with Ad vectors expressing Akt-DN, GSK-3b-CA, or vector alone. Top panel shows representative photomicrographs of increased JC-1 red
fluorescence, indicating increased mitochondrial membrane potential. Bottom panel shows ROS production measured by CM-H2DCFDA.
ROS data are mean 6 SEM from three independent experiments with at least eight technical replicates. All other data are mean 6 SD from
five independent experiments. *P< 0.05. AU, arbitrary unit; d, days; DFO, deferoxamine; dpm, disintegrations per minute; inh, inhibitor; OD,
optical density.
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also prevented high glucose–induced PP2A activation, indi-
cating that extramitochondrial diffusion of H2O2 produced
by Mn-SOD was also necessary for PP2A activation. Finally,
deferoxamine, an iron chelator, also prevented activation of
PP2A by high glucose. Together, these results are consistent
with PP2A activation by hydroxyl radicals generated by the
reaction of H2O2 with free iron released from intramito-
chondrial stores by superoxide (25).
Transient Exposure to High Glucose Induces
a Persistent Increase in Intracellular Free Iron
Mitochondrial superoxide production has been shown to
cause increased free iron by inducing release of the metal
from ferritin (26,27) and from mitochondrial iron-sulfur
cluster proteins (28,29). To determine whether high glucose–
induced mitochondrial superoxide production causes an
increased release of free iron, cellular levels of the metal
were measured by EPR. Free intracellular iron was mea-
sured in HAECs after 1, 2, 3, 4, 5, and 6 h of treatment
with 25 mmol/L glucose. High glucose induced a signifi-
cant increase in free iron levels after 2 h, reaching 2.8-
fold after 6 h (Fig. 2G). Consistent with the persistence of
increased PP2A activity in 5 mmol/L glucose after tran-
sient exposure to 25 mmol/L glucose, increased intracel-
lular free iron levels induced by 6 h exposure to 25 mmol/L
glucose also persisted for 2 days of subsequent exposure
to 5 mmol/L glucose (Fig. 2G, red bar). Overexpression
of Mn-SOD completely prevented high glucose–induced
release of free iron, demonstrating that hyperglycemia-
induced increase in mitochondrial superoxide production
causes release of Fe2+ from intramitochondrial stores.
Mimicking Effects of High Glucose on Different Loop
Components Increases DC and ROS in Cells Exposed
Only to 5 mmol/L Glucose
Detachment of VDAC-bound HK-II in cells incubated in
5 mmol/L glucose increases DC and ROS production to the
same level as does incubation in 25 mmol/L glucose (Fig.
2A). To demonstrate that altering other loop components
has the same effect in cells exposed only to 5 mmol/L
glucose, HAECs were cultured in 5 mmol/L glucose after
infection with adenoviral vectors expressing either Akt-DN
to mimic the effect of high glucose on Akt1 activity or
a constitutively active form of GSK-3b (GSK-3b-CA) to
mimic the effect of high glucose on GSK-3b. Overexpres-
sion of either Akt-DN or GSK-3b-CA induced an increase
in DC and ROS production to the same level as did in-
cubation in 25 mmol/L glucose (Fig. 2H). A schematic
representation of the multicomponent feedback loop
that maintains persistent mitochondrial ROS production
after transient exposure to high glucose is shown in Fig. 3.
Disruption of the Multicomponent Feedback Loop
Reverses the Persistent Left Shift of the Glucose-ROS
Dose-Response Curve Induced by Transient Exposure
to High Glucose
To demonstrate that persistent activation of the multi-
component feedback loop stably shifts the glucose-ROS
dose-response curve to the left, thus maintaining persis-
tently increased mitochondrial ROS in 5 mmol/L glucose
for days after transient exposure to high glucose, cells
were incubated for 6 h in either 5 or 25 mmol/L glucose.
Both groups of cells were then incubated in 5 mmol/L
glucose for 2 days. After that 2-day incubation in 5 mmol/L
glucose, cells transiently exposed to 25 mmol/L glucose
at the beginning of the experiment had activity of the
penultimate loop component GSK-3b normalized for 6 h
using a degradable peptide inhibitor of GSK-3b (Fig. 4A,
orange curve). This curve is shown in comparison with the
curve from cells exposed to 5 mmol/L initially (Fig. 4A,
blue curve) and the curve from cells initially exposed to
25 mmol/L glucose (Fig. 4A, red curve from Fig. 1).
Brief Exposure to 12 mmol/L Glucose Has the Same
Effects on Feedback Loop Components as Transient
Exposure to a Higher Glucose Concentration, and
GLP-1(9–36)amide Prevents This
Because the data in Fig. 1D demonstrate that maximum
ROS production in HAECs occurs at a glucose concentra-
tion of 12 mmol/L with no further increase at higher
glucose concentrations, we next used 12 mmol/L glucose,
a concentration often seen in hyperglycemic spikes in
patients with type 1 diabetes, to show that brief exposure
to this glucose concentration has the same effects on
Figure 3—Schematic representation of the multicomponent feed-
back loop that maintains persistently increased ROS production
after transient exposure to high glucose. Transient exposure to
high glucose induces a transient increase in ETC flux, increasing
DC and thereby increasing mitochondrial superoxide production. In
the mitochondria, this superoxide causes the release of Fe2+ from
ferritin and iron sulfur cluster–containing proteins. This released free
iron reacts with diffused superoxide-derived hydrogen peroxide to
form hydroxyl radicals, which increase PP2A activity. Activated
PP2A then dephosphorylates Akt1, decreasing its activity. Decreased
Akt1 activity increases GSK-3b activity, which then increases VDAC
threonine phosphorylation (P). Increased VDAC threonine phos-
phorylation decreases HK-II association with VDAC, which
increases the DC at physiologic levels of glucose. Operation of
this loop causes a stable left shift of the glucose concentration-
ROS dose-response curve, thereby maintaining increased ROS
levels at normal glucose levels for days after transient exposure
of cells to high glucose.
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Figure 4—GLP-1(9–36)amide reverses the persistent left shift of the glucose concentration-ROS dose-response curve caused by transient
hyperglycemia. A: Glucose concentration-ROS dose-response curves. Glucose concentration-ROS dose-response curves from HAECs
exposed to 25 mmol/L for 6 h followed by 2 days of 5 mmol/L glucose and then transiently treated with a peptide GSK-3b inhibitor (orange
curve). This curve is shown in comparison with the glucose concentration-ROS curves from cells exposed to 5 mmol/L glucose for 2 days
(blue curve) and the curve from cells exposed to 6 h of 25 mmol/L glucose followed by 5 mmol/L glucose for 2 days (red curve) from Fig. 1D.
ROS levels were measured by CM-H2DCFDA. ROS data are mean6 SEM from three independent experiments with at least eight technical
replicates. *P < 0.05. B–E: Effect of GLP-1(9–36)amide on feedback loop components. HAECs were exposed to 25 mmol/L glucose for 6 h
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feedback loop components as brief exposure to a higher
glucose concentration. We also determined the effect of
the GLP-1 cleavage product GLP-1(9–36)amide, which is
rapidly produced in vivo by dipeptidyl peptidase IV cleav-
age, on components of the ROS-generating feedback loop.
HAECs were exposed to 12 mmol/L glucose for 6 h in
the presence or absence of GLP-1(9–36)amide or a GSK-3b
inhibitor peptide and HK-II/VDAC association was evalu-
ated by IP-WB. GLP-1(9–36)amide prevented the high glucose–
induced decrease in HK-II/VDAC association as effectively
as the GSK-3b inhibitor peptide (Fig. 4B). GLP-1(9–36)amide
also prevented the high glucose–induced increase in VDAC
phosphorylation (Fig. 4C), GSK-3b activity measured as
p-GSK-3b (S9)/GSK-3b was increased to the same extent
by 12 mmol/L glucose as it was by higher glucose concentra-
tions. GLP-1(9–36)amide completely prevented this (Fig. 4D).
Moreover, Akt activity was reduced to the same extent by
6 h of exposure to 12 mmol/L glucose as it was by higher
glucose concentrations, and GLP-1(9–36)amide completely
prevented this (Fig. 4E).
Feedback Loop Disruption by the GLP-1 Cleavage
Product GLP-1(9–36)amide Reverses the Persistent Left
Shift of the Glucose Concentration-ROS Dose-
Response Curve After Transient Hyperglycemia,
Thereby Normalizing Persistent ROS Production and Its
Pathophysiologic Consequences in Cultured
Endothelial Cells and in Mice
To demonstrate that GLP-1(9–36)amide reverses the left
shift of the glucose-ROS dose-response curve, HAECs pre-
viously exposed for 6 h to 25 mmol/L glucose followed by
5 mmol/L glucose for 2 days were transiently exposed to
the peptide on day 2, and a glucose concentration-ROS
dose-response experiment was performed. Transient expo-
sure to GLP-1(9–36)amide completely reversed the persis-
tent left-shifted glucose concentration-ROS dose-response
curve (Fig. 4F, green curve). The glucose concentration-ROS
dose-response obtained is superimposed on the curve from
cells exposed to 5 mmol/L glucose for 2 days (blue curve)
and from cells exposed to 6 h of 25 mmol/L glucose followed
by 5 mmol/L glucose for 2 days (red curve) from Fig. 1. The
effect of GLP-1(9–36)amide and its precursor peptide
GLP-1(7–36)amide on ROS generation after transient expo-
sure to 25 mmol/L glucose is shown in Supplementary Fig. 3.
ROS induced by high glucose directly inhibit the activity
of the endothelial cell enzyme PGI2 (30). In experimental
diabetes, this has been shown to accelerate both nephrop-
athy and cardiac fibroblast proliferation (31–33).
In cultured HAECs, prostacyclin activity was reduced
80% after 2 days’ incubation in 5 mmol/L glucose after
prior transient exposure to 25 mmol/L glucose (data not
shown). To demonstrate that transient hyperglycemia
also induces persistent ROS production and consequent
PGI2 inhibition in vivo, we measured PGI2 activity in
a transient hyperglycemia mouse model (18). In nondia-
betic mice, PGI2 activity was measured in mouse aortas 6
days after transient hyperglycemia, and despite normal
glucose metabolism for 6 days, PGI2 activity was still re-
duced.90% (Fig. 5, bar 2). Because the half-life of PGI2 is
2.5 h (34), the persistent inhibition of its activity for 6
days in normoglycemic, nondiabetic mice after transient
hyperglycemia is consistent with continuous production
of ROS maintained by the multicomponent feedback loop.
To test this hypothesis, continuous ROS production was
blocked by transient treatment with GLP-1(9–36)amide.
Two days after transient hyperglycemia, a micro-osmotic
pump containing GLP-1(9–36)amide (300 mg/mL) was
inserted in the mice for 24 h and then removed (Fig. 5,
top panel). As shown in Fig. 5, bar 3, 3 days after the
GLP-1(9–36)amide was removed, the dramatic reduction of
PGI2 activity, which persisted for 6 days in nondiabetic
animals after transient hyperglycemia (Fig. 5, bar 2), was
completely normalized. Because in mouse liver the half-life
of GLP-1(9–36)amide is 52 min and that of its potentially
bioactive cleavage product GLP-1(28–36)amide is 13 min
(35), the persistent effect on PGI2 activity is most consis-
tent with disruption of the ROS-generating feedback loop
established by transient hyperglycemia.
DISCUSSION
In this study, we show that 4–6 h of exposure to a level of
high glucose frequently seen in the glycemic spikes of
patients with type 1 diabetes activates a multicomponent
feedback loop that causes a stable left shift of the glucose
concentration-ROS dose-response curve. This left shift
causes persistent mitochondrial overproduction of ROS
for days after glucose concentration is normalized. In
HAECs, the GLP-1 cleavage product GLP-1(9–36)amide re-
versed the persistent left shift caused by transient hyper-
glycemia. Similarly, in nondiabetic mice, brief disruption
of the feedback loop with GLP-1(9–36)amide 2 days after
transient hyperglycemia normalized persistent ROS inac-
tivation of endothelial cell PGI2, a defect believed to play
an important role in the pathogenesis of both diabetic
nephropathy and cardiac fibrosis (30–32).
with or without 100 pmol/L GLP-1(9–36)amide. Cells exposed to 5 mmol/L glucose were used as controls (blue bars). B: HK-II/VDAC as-
sociation. A peptide inhibitor of GSK-3b was used as control. C: VDAC phosphorylation: quantitation of IP-WB data. D: GSK-3b phos-
phorylation. Top panel shows IP-WB of GSK-3b:GSK-3b and GSK-3b:p-GSK-3b (S9). Bottom panel shows quantitation of IP-WB data
from top panel. E: Akt1 activity. Data are mean 6 SD from five independent experiments. *P < 0.01. F: Effect of GLP-1(9–36)amide on
glucose concentration-ROS dose-response curves. Glucose concentration-ROS dose-response curve from HAECs exposed to 25 mmol/L
for 6 h followed by 2 days of 5 mmol/L glucose and then transiently treated with GLP-1(9–36)amide (green curve). This curve has been
superimposed on the glucose concentration-ROS curves from A. ROS levels were measured by CM-H2DCFDA. ROS data are mean6 SEM
from three independent experiments with at least eight technical replicates. *P < 0.05. AU, arbitrary unit; d, days; inh, inhibitor.
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Because hyperglycemia-induced overproduction of mito-
chondrial ROS also initiates many of the other complex
series of molecular events that result in diabetic tissue
damage (36), these data suggest that hyperglycemic spikes
high enough to activate persistent ROS production during
subsequent periods of normal glycemia but too brief to
affect the HbA1c value are a major determinant of the
89% of diabetes complications risk not captured by HbA1c
(3). The stable left shift of the glucose concentration-ROS
dose-response curve induced by short exposure to high
glucose is an example of bistability, a fundamental property
of many biological systems in which the system can be in
either of two alternative, stable steady states (37,38). Bist-
ability is based on the continued activation or inhibition of
feedback loops. For example, transient exposure of Xenopus
oocytes to progesterone induces stable cellular differentia-
tion, which persists in the absence of progesterone (37).
Similarly, both stable transformation of differentiated cells
into induced pluripotent stem cells and stable transforma-
tion of embryonic stem cells into differentiated cells involve
stable feedback loops initiated by transient exposure to
a small number of transcription factors (39,40).
In this study, 1 h of transient exposure to high glucose
maximally increased ROS in HAECs. However, 4–6 h of
exposure to high glucose were required for the persistent
generation of ROS after normoglycemia restoration.
These data suggest that a critical change in other loop
components takes at least 4 h to establish. It may also
reflect the time course of other ROS-mediated effects.
Why does increased ROS not activate a negative feed-
back loop to restore homeostasis as proposed by Brand and
colleagues (41)? A plausible answer is suggested by the
work of Harper and colleagues (42,43) who confirmed
that uncoupling proteins (UCPs) 2 and 3 are activated by
ROS and discovered that reversible posttranslational mod-
ification of UCPs with glutathione reverses ROS-mediated
activation of UCPs. Because mitochondrial ROS can trigger
both protein glutathionylation and protein deglutathiony-
lation through the enzyme glutaredoxin 2, 4–6 h of suffi-
ciently high levels of ROS in the presence of high glucose
may adversely affect S-glutathionylation of UCPs and
a number of other mitochondrial proteins (42).
In the current study, GLP-1(9–36)amide was shown to
prevent the excess VDAC phosphorylation induced by tran-
sient hyperglycemia, the excess activation of GSK-3b re-
sponsible for this, and the decreased association of HK-II
with VDAC and to prevent the inhibition of Akt activity
caused by transient hyperglycemia. As a result, GLP-1(9–
36)amide reversed the persistent left shift of the glucose
concentration-ROS dose-response curve caused by transient
hyperglycemia and thereby reversed the ROS-dependent
inactivation of PGI2. GLP-1(9–36)
amide is the cleavage
product of the incretin hormone GLP-1(7–36)amide. Studies
have shown that GLP-1(9–36)amide, initially considered to
be an inactive degradation product of GLP-1, performs
important physiologic functions distinct from its precursor
(12). GLP-1(9–36)amide has been reported to have unique
extrapancreatic insulin-like actions in the heart, vascula-
ture, and liver, which appear not to be mediated through
the GLP-1 receptor (35). In HAECs, GLP-1(9–36)amide acti-
vate cardioprotective signaling pathways, whereas GLP-1
receptor agonists do not (44). Whether the effects of
GLP-1(9–36)amide in the current study are mediated
through an unidentified cell surface receptor or through
Figure 5—GLP-1(9–36)amide reverses the persistent reduction of PGI2 caused by transient hyperglycemia in vivo. Top panel shows
experiment schematic. Bottom panel shows findings in C57BL/6 mice (n = 5/group) that received four sequential injections of glucose
3 g/kg i.p. (red bars) or an equivalent volume of 0.9% saline (blue bar) at 2-h intervals. Two days after transient hyperglycemia, a micro-
osmotic pump containing GLP-1(9–36)amide (300 mg/mL) was inserted in the mice for 24 h and then removed. Aortas were removed and
PGI2 activity measured in all groups 6 days after initial glucose or saline injections. Data are mean 6 SD. *P < 0.01. d, days.
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further degradation to a nonapeptide possibly targeted to
mitochondria remains to be elucidated.
Paneni et al. (45) proposed an ROS-generating feed-
back loop in HAECs consisting of two components:
p66Shc and protein kinase C (PKC) bII. They reported that
continuous exposure of endothelial cells to 25 mmol/L
glucose increased expression of the adaptor protein p66Shc
and activated p66Shc by a PKC bII–dependent mechanism.
In contrast, in the current experiments, we did not ob-
serve any change in either p66Shc protein levels or in-
creased p66Shc phosphorylation (data not shown). Our
observations that GLP-1(9–36)amide prevents the high
glucose–induced changes in feedback loop components
identified in this study and that this peptide reverses
persistent ROS inactivation of PGI2 after transient hy-
perglycemia in nondiabetic mice support the feedback
loop elucidated here.
Hyperglycemia-induced overproduction of mitochon-
drial ROS initiates many of the complex series of
molecular events that result in diabetic tissue damage
(36), and transgenic expression of the antioxidant enzyme
SOD prevents each complication in experimental diabetes
(46–48). We have previously observed (49) that in endo-
thelial Rho-zero (cells that have been depleted of their
own mitochondrial DNA by prolonged incubation with
ethidium bromide and consequently lacking functional
mitochondria), exposure to high glucose failed to increase
ROS production (50). Thus, it appears that the mitochon-
dria are required for the initiation of hyperglycemia-
induced superoxide production. Published evidence has
indicated that this in turn can activate a number of other
superoxide production pathways that may amplify the
original damaging effect of hyperglycemia, including acti-
vation of NADPH oxidases and uncoupling of endothelial
nitric oxide synthase (6).
Because the major cause of death in people with type 1
diabetes is cardiovascular disease (CVD), HAECs were
used in the current study. During the DCCT, the small
number of CVD events in the relatively young cohort
precluded a determination of the effect of HbA1c on the
risk of CVD. However, the DCCT data show that at least
89% of variation in risk of diabetic retinopathy and a sim-
ilar percentage of risk of microalbuminuria or albuminuria
are not captured by mean HbA1c values (2,3). In 2005,
long-term follow-up data on the DCCT/EDIC cohort showed
no difference in mean HbA1c values between the two EDIC
study groups. However, the hazard ratio for risk of non-
fatal myocardial infarction, stroke, or death from CVD
was increased 2.5- to 2.9-fold in patients with either
microalbuminuria or albuminuria (51).
The data presented here suggest that the 89% of
variation in risk of diabetic microalbuminuria or albu-
minuria not captured by mean HbA1c values in the DCCT
cohort may reflect transient above-threshold spikes of
hyperglycemia that continue to activate damaging mech-
anisms for days of subsequent near-normal glycemia. The
phenomenon and mechanism described in this study
provide a basis for the development of new biomarkers
to complement HbA1c and novel therapeutic agents, in-
cluding GLP-1(9–36)amide, for the prevention and treat-
ment of diabetes complications.
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